Literature DB >> 19836487

Insulinoma.

Aarti Mathur1, Philip Gorden, Steven K Libutti.   

Abstract

Insulinoma is a rare neuroendocrine tumor with an incidence of 4 per 1 million persons per year, which may occur as a unifocal sporadic event in patients without an inherited syndrome or as a part of multiple endocrine neoplasia type 1. Key neuroglycopenic and hypoglycemic symptoms in conjunction with biochemical proof establish the diagnosis. Once the diagnosis is established, the insulinoma is preoperatively localized within the pancreas with the goal of surgical excision for cure. This review discusses the historical background, diagnosis, and management of sporadic insulinoma.

Entities:  

Mesh:

Year:  2009        PMID: 19836487      PMCID: PMC3470467          DOI: 10.1016/j.suc.2009.06.009

Source DB:  PubMed          Journal:  Surg Clin North Am        ISSN: 0039-6109            Impact factor:   2.741


  66 in total

1.  Natural history of a proinsulin-secreting insulinoma: from symptomatic hypoglycemia to clinical diabetes.

Authors:  E Arioglu; N A Gottlieb; C A Koch; J L Doppman; N J Grey; P Gorden
Journal:  J Clin Endocrinol Metab       Date:  2000-10       Impact factor: 5.958

2.  Intraoperative ultrasonographic localization of islet cell tumors. A prospective comparison to palpation.

Authors:  J A Norton; D T Cromack; T H Shawker; J L Doppman; R Comi; P Gorden; P N Maton; J D Gardner; R T Jensen
Journal:  Ann Surg       Date:  1988-02       Impact factor: 12.969

Review 3.  Diagnostic approach to adults with hypoglycemic disorders.

Authors:  F J Service
Journal:  Endocrinol Metab Clin North Am       Date:  1999-09       Impact factor: 4.741

4.  Laparoscopic radiofrequency ablation of neuroendocrine liver metastases.

Authors:  Eren Berber; Nora Flesher; Allan E Siperstein
Journal:  World J Surg       Date:  2002-05-21       Impact factor: 3.352

Review 5.  Hepatic surgery for metastases from neuroendocrine tumors.

Authors:  Juan M Sarmiento; Florencia G Que
Journal:  Surg Oncol Clin N Am       Date:  2003-01       Impact factor: 3.495

6.  Aggressive surgery for metastatic liver neuroendocrine tumors.

Authors:  Jeffrey A Norton; Robert S Warren; Mary G Kelly; Marlene B Zuraek; Robert T Jensen
Journal:  Surgery       Date:  2003-12       Impact factor: 3.982

7.  Liver transplantation for gastroenteropancreatic neuroendocrine cancers: Defining selection criteria to improve survival.

Authors:  Frederike G I van Vilsteren; Edwina S Baskin-Bey; David M Nagorney; Schuyler O Sanderson; Walter K Kremers; Charles B Rosen; Gregory J Gores; Timothy J Hobday
Journal:  Liver Transpl       Date:  2006-03       Impact factor: 5.799

8.  Pancreatic insulinomas.

Authors:  F Menegaux; G Schmitt; M Mercadier; J P Chigot
Journal:  Am J Surg       Date:  1993-02       Impact factor: 2.565

9.  Is laparoscopic resection adequate in patients with neuroendocrine pancreatic tumors?

Authors:  Laureano Fernández-Cruz; Laia Blanco; Rebeca Cosa; Héctor Rendón
Journal:  World J Surg       Date:  2008-05       Impact factor: 3.352

10.  Localization of insulinomas to regions of the pancreas by intraarterial calcium stimulation: the NIH experience.

Authors:  Jean-Marc Guettier; Anthony Kam; Richard Chang; Monica C Skarulis; Craig Cochran; H Richard Alexander; Steven K Libutti; James F Pingpank; Phillip Gorden
Journal:  J Clin Endocrinol Metab       Date:  2009-02-03       Impact factor: 5.958

View more
  23 in total

1.  Metabolic acidosis as a complication of intravenous dextrose administration in a patient with insulinoma.

Authors:  Agustín Ramos-Prol; Maribel del Olmo-García; Antonia Pérez-Lázaro; María Caballero-Soto; María Argente-Pla; Beatriz León-de Zayas; Juan Francisco Merino-Torres
Journal:  Endocrine       Date:  2010-10-23       Impact factor: 3.633

Review 2.  The functioning side of the pancreas: a review on insulinomas.

Authors:  I Maggio; V Mollica; N Brighi; G Lamberti; L Manuzzi; A D Ricci; D Campana
Journal:  J Endocrinol Invest       Date:  2019-07-31       Impact factor: 4.256

Review 3.  [Early endocrine neoplasia of the pancreas].

Authors:  V Fendrich; D K Bartsch
Journal:  Chirurg       Date:  2018-04       Impact factor: 0.955

Review 4.  Care for patients with multiple endocrine neoplasia type 1: the current evidence base.

Authors:  C R C Pieterman; M R Vriens; K M A Dreijerink; R B van der Luijt; G D Valk
Journal:  Fam Cancer       Date:  2011-03       Impact factor: 2.375

5.  Insulinoma-Accurate Preoperative Localization Is the Key to Management: An Initial Experience.

Authors:  Ajay Sharma; Peeyush Varshney; Rajeev Kasliwal; Anand Nagar; Krishnavardhan Venkatatelikicherla; Shashwat Sarin; R P Choubey; V K Kapoor
Journal:  Indian J Surg Oncol       Date:  2022-04-26

Review 6.  Surgical Therapy of Sporadic Pancreatic Neuroendocrine Neoplasias G1/G2.

Authors:  Volker Fendrich; Detlef K Bartsch
Journal:  Visc Med       Date:  2017-10-04

7.  Insulinoma and anaesthetic implications.

Authors:  Jyotsna Goswami; Pallavi Somkuwar; Yogesh Naik
Journal:  Indian J Anaesth       Date:  2012-03

8.  ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes.

Authors:  Robert T Jensen; Guillaume Cadiot; Maria L Brandi; Wouter W de Herder; Gregory Kaltsas; Paul Komminoth; Jean-Yves Scoazec; Ramon Salazar; Alain Sauvanet; Reza Kianmanesh
Journal:  Neuroendocrinology       Date:  2012-02-15       Impact factor: 4.914

9.  A case of inoperable malignant insulinoma with resistant hypoglycemia who experienced the most significant clinical improvement with everolimus.

Authors:  Emre Bozkirli; Okan Bakiner; Huseyin Abali; Cagatay Andic; Ali Fuat Yapar; Fazilet Kayaselcuk; Eda Ertorer
Journal:  Case Rep Endocrinol       Date:  2013-05-08

10.  Chromogranin A is a reliable serum diagnostic biomarker for pancreatic neuroendocrine tumors but not for insulinomas.

Authors:  Xin-Wei Qiao; Ling Qiu; Yuan-Jia Chen; Chang-Ting Meng; Zhao Sun; Chun-Mei Bai; Da-Chun Zhao; Tai-Ping Zhang; Yu-Pei Zhao; Yu-Li Song; Yu-Hong Wang; Jie Chen; Chong-Mei Lu
Journal:  BMC Endocr Disord       Date:  2014-08-07       Impact factor: 2.763

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.